Executive Summary

The blenrep (belantamab mafodotin-blmf) story in multiple myeloma

Positive results from GSK's latest trials could mark Blenrep's potential return as a promising treatment for relapsed refractory multiple myeloma.  

The 2023 oncology medicine approvals from the European Medicines Agency (EMA)

This executive summary focuses specifically on the oncology medicine approvals and in particular, those that were approved under a CMA.

The age of gene editing: The first EMA approval of a CRISPR-CAS9 medicine for beta thalassaemia and sickle cell disease

The first gene-editing medicinal product (GEMP) has been approved by the European Medicines Agency (EMA). What does this mean for the wider regulatory landscape?

Biomarker-driven oncology therapeutics and whole genome cancer sequencing: an executive summary

Results from the 100,000 Genomes Cancer Programme offer new insights for precision oncology.